Shrivastava Neha, Taneja Rashmi, Kumari Mamta, Sood Rajesh, Grover Niharika
Department of Anaesthesia, ESIC Medical College, Faridabad, Haryana, India.
J Anaesthesiol Clin Pharmacol. 2025 Apr-Jun;41(2):250-256. doi: 10.4103/joacp.joacp_232_24. Epub 2025 Jan 29.
Postoperative pain is a major cause of discomfort after laparoscopic surgeries and thus necessitates prevention and treatment. This study aims to evaluate and compare two different doses of intraperitoneally nebulized (aerosol size: 0.4-4.5 micrometers) dexamethasone for the prevention of postoperative pain.
In this double-blind, randomized control study, 135 patients undergoing laparoscopic surgeries were randomly assigned to three groups after obtaining ethical committee clearance and CTRI registration. Intraperitoneal nebulization was performed using the Aeroneb device, with group A receiving 16 mg dexamethasone, group B receiving 8 mg dexamethasone, and group C receiving 0.9% normal saline. The primary outcome was assessed by measuring visceral, somatic, and referred pain using a visual analog scale (VAS) at 6 hours postoperatively. Secondary outcomes included VAS at 1 and 24 hours, the hemodynamic response to pneumo-peritoneum, 24-hour anti-emetics, and opioid consumption.
VAS score at 6 hours was 0.9 ± 1.06 in group A, 1.7 ± 1.45 in group B, and 2.3 ± 1.87 in group C for referred pain; the values were statistically significant ( = 0.01). VAS score was 0.7 ± 0.76 in group A, 1.7 ± 1.82 in group B, and 2.2 ± 2.06 in group C for dull aching pain; the results were statistically significant at 24 hours ( = 0.001). None of the values at any time point were statistically significant ( < 0.05) for incisional pain. The rise in heart rate after 5 minutes of pneumoperitoneum was the least in group A compared to group C ( = 0.01). Group C had the highest consumption of anti-emetics and rescue analgesics ( = 0.001).
Intraperitoneal dexamethasone nebulization of 16 mg and 8 mg both are equi-effective in decreasing the severity of pain after laparoscopic surgeries compared to normal saline nebulization ( = 0.001).
术后疼痛是腹腔镜手术后不适的主要原因,因此需要预防和治疗。本研究旨在评估和比较两种不同剂量的腹腔内雾化(气溶胶大小:0.4 - 4.5微米)地塞米松预防术后疼痛的效果。
在这项双盲、随机对照研究中,135例接受腹腔镜手术的患者在获得伦理委员会批准和CTRI注册后被随机分为三组。使用Aeroneb设备进行腹腔内雾化,A组接受16毫克地塞米松,B组接受8毫克地塞米松,C组接受0.9%生理盐水。主要结局通过术后6小时使用视觉模拟量表(VAS)测量内脏痛、躯体痛和牵涉痛来评估。次要结局包括术后1小时和24小时的VAS、对气腹的血流动力学反应、24小时的止吐药使用情况和阿片类药物消耗量。
A组、B组和C组术后6小时牵涉痛的VAS评分分别为0.9±1.06、1.7±1.45和2.3±1.87;差异具有统计学意义(P = 0.01)。A组、B组和C组钝痛的VAS评分分别为0.7±0.76、1.7±1.82和2.2±2.06;在24小时时结果具有统计学意义(P = 0.001)。切口痛在任何时间点的数值均无统计学意义(P < 0.05)。与C组相比,A组气腹5分钟后心率升高幅度最小(P = 0.01)。C组止吐药和急救镇痛药的消耗量最高(P = 0.001)。
与生理盐水雾化相比,16毫克和8毫克腹腔内地塞米松雾化在降低腹腔镜手术后疼痛严重程度方面效果相当(P = 0.001)。